pazopanib   Click here for help

GtoPdb Ligand ID: 5698

Synonyms: GW 786034 | indazolylpyrimidine 13 [4] | Votrient®
Approved drug
pazopanib is an approved drug (FDA (2009), EMA (2010))
Compound class: Synthetic organic
Comment: Pazopanib is a Type-1 kinase inhibitor. Its discovery is reported in [5]. It targets multiple receptor tyrosine kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRβ, FGFR1, Kit and CSF1R).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pazopanib

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 127.41
Molecular weight 437.16
XLogP 3.34
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN(c1ccc2c(c1)nn(c2C)C)c1ccnc(n1)Nc1ccc(c(c1)S(=O)(=O)N)C
Isomeric SMILES CN(c1ccc2c(c1)nn(c2C)C)c1ccnc(n1)Nc1ccc(c(c1)S(=O)(=O)N)C
InChI InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
No information available.
Summary of Clinical Use Click here for help
Used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma.
Marketed formulations contain pazopanib hydrochloride (PubChem CID 11525740).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Pazopanib (a synthetic indazolylpyrimidine) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and PDGFR-β, fibroblast growth factor receptor (FGFR)-1 and FGFR-3, cytokine receptor, interleukin-2 receptor inducible T-cell kinase, leukocyte-specific protein tyrosine kinase, and transmembrane glycoprotein receptor tyrosine kinase. Many of these receptor targets are part of the pathway involved in neoangiogenesis in tumours and are essential for tumour survival and growth. Pazozanib can reach circulating concentrations of >15µg/ml which is sufficient to elicit significant alterations in indicators of tumour regression (reduction in tumour blood flow, increased tumour apoptosis, inhibition of tumour growth, reduction in tumour interstitial fluid pressure, and hypoxia in cancer cells) in patients undergoing treatment.
Pharmacokinetics Click here for help
Maximum plasma concentration is reached in 2-4h following oral administration. The major circulating component of the drug is pazopanib, and not its metabolites. Bioavailability may be low due to incomplete absorption from the gastrointestinal tract. Bioavailability can be increased by administering as a crushed tablet and if taken before or after eating. Protein binding is greater than 99%.
Metabolized in the liver mainly by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8. Only one of its metabolites can inhibit the proliferation of VEGF-stimulated HUVEC cells with a similar potency to that of the parent compound, but as this constitutes a very small proportion of the administered dose in the system, it is assumed that the activity of pazopanib is mainly dependent on parent pazopanib exposure.
Elimination is primarily via feces (82.2%) with <4% in the urine.
Organ function impairment
Renal impairment is unlikely to significantly affect the pharmacokinetics of pazopanib as less than 4% is eliminated via the kidneys although due to a lack of experience in this group, caution is advised in patients with creatinine clearance below 30 ml/min. Based on safety and tolerability data, the dosage of pazopanib should be reduced to 200 mg once daily in subjects with moderate hepatic impairment. As a result of diminished exposure and limited hepatic reserve pazopanib is not recommended in patients with severe hepatic impairment
External links Click here for help